Immunocore (IMCR) stock price, revenue, and financials

Immunocore market cap is $1.6 b, and annual revenue was $30.11 m in FY 2020

$1.6 B

IMCR Mkt cap, 07-Apr-2021

$30.1 M

Immunocore Revenue FY, 2020
Immunocore Cash, 31-Dec-2020129.7 M

Immunocore Revenue Breakdown

Embed Graph

Immunocore revenue breakdown by business segment: 22.4% from GlaxoSmithKline, 74.4% from Genentech and 3.2% from Other

Immunocore revenue breakdown by geographic segment: 22.4% from United Kingdom and 77.6% from United States

Immunocore Income Statement

Annual

GBPFY, 2018FY, 2019FY, 2020

Revenue

23.7m25.7m30.1m

Revenue growth, %

9%

R&D expense

83.6m100.0m

General and administrative expense

34.2m44.2m

Operating expense total

117.7m144.2m

EBIT

(93.5m)(118.3m)

EBIT margin, %

(395%)(461%)

Interest expense

842.0k3.8m

Interest income

822.0k1.4m

Pre tax profit

(88.2m)(126.2m)(87.4m)

Income tax expense

(16.5m)(22.3m)(13.3m)

Net Income

(71.6m)(103.9m)

EPS

0.00.0

Immunocore Balance Sheet

Annual

GBPFY, 2018FY, 2019FY, 2020

Cash

124.4m74.0m129.7m

Accounts Receivable

4.4m1.5m

Prepaid Expenses

7.6m4.5m

Current Assets

171.2m124.3m152.9m

PP&E

20.9m54.9m13.8m

Total Assets

195.8m185.6m197.2m

Accounts Payable

6.4m15.7m

Short-term debt

21.1m

Current Liabilities

49.6m84.5m55.0m

Long-term debt

18.9m38.3m

Non-Current Liabilities

89.6m86.4m86.9m

Total Debt

18.9m59.4m

Total Liabilities

139.2m170.9m141.8m

Additional Paid-in Capital

224.1m283.3m

Retained Earnings

(175.2m)(279.1m)(349.9m)

Total Equity

56.6m14.8m55.3m

Debt to Equity Ratio

0.3 x4 x

Debt to Assets Ratio

0.1 x0.3 x

Financial Leverage

3.5 x12.6 x3.6 x

Quarterly

GBPQ3, 2020

Cash

56.7m

Accounts Receivable

136.0k

Prepaid Expenses

5.5m

Current Assets

76.8m

PP&E

45.1m

Total Assets

130.8m

Accounts Payable

5.8m

Short-term debt

2.1m

Current Liabilities

47.5m

Long-term debt

32.0m

Non-Current Liabilities

67.8m

Total Debt

34.1m

Total Liabilities

115.3m

Common Stock

1.0k

Additional Paid-in Capital

330.4m

Retained Earnings

(331.0m)

Total Equity

15.5m

Debt to Equity Ratio

2.2 x

Debt to Assets Ratio

0.3 x

Financial Leverage

8.4 x

Immunocore Cash Flow

Annual

GBPFY, 2018FY, 2019FY, 2020

Net Income

(71.6m)(103.9m)

Depreciation and Amortization

6.7m9.2m

Accounts Receivable

(1.5m)1.8m

Accounts Payable

5.3m9.9m

Cash From Operating Activities

(16.6m)(101.4m)(60.6m)

Purchases of PP&E

(3.5m)(4.1m)

Cash From Investing Activities

58.0m(4.1m)467.0k

Long-term Borrowings

(4.0m)

Cash From Financing Activities

101.0k55.1m115.9m

Net Change in Cash

41.5m(50.4m)

Quarterly

GBPQ3, 2019Q3, 2020

Net Income

(78.0m)(55.2m)

Depreciation and Amortization

6.9m6.7m

Accounts Receivable

(857.0k)(612.0k)

Accounts Payable

5.8m(6.2m)

Cash From Operating Activities

(75.7m)(40.0m)

Purchases of PP&E

(2.4m)(2.7m)

Cash From Investing Activities

(2.5m)(1.3m)

Long-term Borrowings

(3.0m)(3.3m)

Cash From Financing Activities

56.2m24.0m

Net Change in Cash

(22.1m)(17.4m)

Immunocore Ratios

USDFY, 2018

Revenue/Employee

65.6k

Debt/Equity

0.3 x

Debt/Assets

0.1 x

Financial Leverage

3.5 x

Immunocore Operating Metrics

Oct, 2020

Patent Applications (Foreign)

81

Patent Applications (US)

8

Patent Cooperation Treaty Applications

7

Patents (Foreign)

145

Patents (US)

6

Immunocore Employee Rating

3.276 votes
Culture & Values
3
Work/Life Balance
3.5
Senior Management
2.4
Salary & Benefits
2.4
Career Opportunities
2.2
Source